We are live on ! Find out more
AGMB icon

AgomAb Therapeutics

32 hedge funds and large institutions have $245M invested in AgomAb Therapeutics in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.45% more ownership

Funds ownership: 0% → 47.45% (+47%)

Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.39%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.04%
New
32
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AGMB Hedge Fund Activity: Q1 2026 in Review

32 of the 8,239 institutional investors tracked by Wall St. Rank reported a position in AgomAb Therapeutics (AGMB) for Q1 2026, worth a combined $245M.

Buyers outnumbered sellers: 32 funds opened new AGMB positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was EQT Fund Management, opening a new position worth an estimated $72.8M.

  • 32 institutional investors held AgomAb Therapeutics (AGMB) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $245M of AgomAb Therapeutics stock for Q1 2026.
  • 32 funds opened new AgomAb Therapeutics positions in Q1 2026 and 0 closed out, a net change of +32 holders.
  • The largest AgomAb Therapeutics buyer in Q1 2026 was EQT Fund Management, an estimated $72.8M added.

Based on aggregated 13F filings for Q1 2026.